Puma Biotechnology (PBYI) Non-Current Deffered Revenue (2011 - 2018)
Puma Biotechnology (PBYI) posted Non-Current Deffered Revenue of $5.8 million for Q4 2018, down 1.04% on a QoQ basis from $5.9 million in Q3 2018, and up 7.57% year-over-year from $5.4 million in Q4 2017.
Puma Biotechnology (PBYI) Non-Current Deffered Revenue (2011 - 2018) Analysis & Trends
Puma Biotechnology's Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $5.8 million for Q4 2018.
- Quarterly Non-Current Deffered Revenue rose 7.57% year-over-year to $5.8 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $5.8 million (up 7.57% YoY) and the FY2018 annual result came in at $5.8 million, up 7.57% from the prior year.
- Non-Current Deffered Revenue was $5.8 million for Q4 2018 at Puma Biotechnology, down from $5.9 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $5.9 million in Q3 2018 and bottomed at $1.1 million in Q3 2014.
- A 5-year average of $3.6 million and a median of $5.1 million in 2016 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2016 — Non-Current Deffered Revenue decreased 9.86% — and 2017, when it jumped 314.93%.
- Puma Biotechnology's Non-Current Deffered Revenue stood at $1.3 million in 2014, then increased by 9.77% to $1.4 million in 2015, then jumped by 295.19% to $5.5 million in 2016, then retreated by 1.8% to $5.4 million in 2017, then gained by 7.57% to $5.8 million in 2018.
- Business Quant data shows PBYI's Non-Current Deffered Revenue at $5.8 million in Q4 2018, $5.9 million in Q3 2018, and $5.5 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Puma Biotechnology | 407.27 Mn | 368.99 Mn | 34.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 5.82 Mn |
| Sep 30, 2018 | 5.88 Mn |
| Jun 30, 2018 | 5.52 Mn |
| Mar 31, 2018 | 5.51 Mn |
| Dec 31, 2017 | 5.41 Mn |
| Sep 30, 2017 | 5.44 Mn |
| Jun 30, 2017 | 5.47 Mn |
| Mar 31, 2017 | 5.50 Mn |
| Dec 31, 2016 | 5.51 Mn |
| Sep 30, 2016 | 5.28 Mn |
| Jun 30, 2016 | 4.85 Mn |
| Mar 31, 2016 | 1.33 Mn |
| Dec 31, 2015 | 1.39 Mn |
| Sep 30, 2015 | 1.45 Mn |
| Jun 30, 2015 | 1.48 Mn |
| Mar 31, 2015 | 1.47 Mn |
| Dec 31, 2014 | 1.27 Mn |
| Sep 30, 2014 | 1.09 Mn |
| Jun 30, 2014 | 1.11 Mn |
| Mar 31, 2014 | 1.22 Mn |